Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
NCT00100009 · View on ClinicalTrials.gov ↗
Study Summary
This study will test the safety and effectiveness of combining a laser treatment called photodynamic therapy, or PDT, with injections into the eye of the steroid triamcinolone acetonide for treating age-related macular degeneration (AMD). The macula is the part of the retina in the back of the eye that determines central or best vision. AMD can severely impair central vision, affecting a person's ability to read, drive, and carry out daily activities. This vision loss is caused by the formation of abnormal blood vessels behind the retina that leak blood under the macula. PTD stops the growth of these blood vessels and slows the rate of vision loss; however, it has only a temporary effect and does not work in all patients. Furthermore, it may actually cause some swelling and re-growth of blood vessels. Triamcinolone acetonide can help lessen swelling and scarring. Patients 50 years of age and older with AMD may be eligible for this study. Candidates are screened with a medical history, medical evaluation, and eye examinations (see below). Participants are randomly assigned to one of three treatment groups: 1) PDT plus 1 mg TAC-PF; 2) PDT plus 4 mg TAC-PF; or 3) PDT plus sham injection (a syringe with no needle is pressed against the eye). Treatments are given the day the patient enrolls in the study and then every 3 months for 2 years, as long as the therapy is thought beneficial. Patients who must discontinue TAC-PF injections may still be treated with PDT if medically necessary. In addition to treatment, patients undergo the following tests and procedures: * Eye examination: Visual acuity and eye pressure are measured, and the lens, retina, pupils and eye movements are examined. * Fundus photography: Photographs of the back of the eye are taken using a special camera with a bright flash. * Lens photography: Photographs of the lens are taken to look for development of cataracts. * Fluorescein angiography: Pictures of the retina are taken to look for abnormal blood
Conditions Studied
Interventions
- DRUG Triamcinolone Acetonide
- DRUG TAC-PF
Study Locations (20)
Florida
- Bascom Palmer Eye Institute — Miami
- Central Florida Retina (CFROL) — Orlando
- Retina Associates of Florida — Tampa
Maryland
- Elman Retina Group, P.A. - Baltimore (ERGBM) — Baltimore
- National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda
- Elman Retina Group, P.A. - Pikesville (ERGPM) — Pikesville
Oregon
- Casey Eye Institute-Portland, OR (CEIPO) — Portland
- Retina Northwest (RNWPO) — Portland
Tennessee
- Southeastern Retina Associates (SRAKT) — Knoxville
- Vanderbilt University — Nashville
Arizona
- Retina Associates Southwest (RASTA) — Tucson
California
- Doheny Eye Institute — Los Angeles
Indiana
- Midwest Eye Institute — Indianapolis
Michigan
- University of Michigan — Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-12-09 |
| Est. Completion | 2006-12-20 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100009
The ClinicalTrials.gov registry entry for NCT00100009 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Eye Institute (NEI), which has 214 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 2 interventions — of which Triamcinolone Acetonide is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00100009 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Florida, Maryland, Oregon. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00100009 about?
NCT00100009 is a clinical study titled "Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration". This study will test the safety and effectiveness of combining a laser treatment called photodynamic therapy, or PDT, with injections into the eye of the steroid triamcinolone acetonide for treating age-related macular degeneration (AMD). The macula is the part of the retina in the back of the eye t...
What is the current status of trial NCT00100009?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2004-12-09. Estimated completion is 2006-12-20.
What conditions does trial NCT00100009 study?
This clinical trial studies the following conditions: Macular Degeneration. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00100009?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), TAC-PF (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00100009?
This trial is sponsored by National Eye Institute (NEI), which has 214 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00100009 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.